Intuniv: Mechanism of Action and Side Effects
Intuniv (extended-release guanfacine) works by selectively stimulating alpha-2A adrenergic receptors in the prefrontal cortex to strengthen neural network connectivity and improve attention and impulse control, and its most common side effects are somnolence, fatigue, low blood pressure, and low heart rate. 1
How Intuniv Works
Guanfacine is a selective central alpha-2A adrenergic receptor agonist with 15-20 times higher affinity for this receptor subtype compared to other alpha-2 receptor subtypes 1. Importantly, it is NOT a central nervous system stimulant 1.
Mechanism in the Brain:
- Acts on prefrontal cortex networks by inhibiting cAMP-PKA-potassium channel signaling on dendritic spines 2
- This strengthens synaptic connections in prefrontal cortex microcircuits, enhancing neuronal firing and improving working memory, attention, and executive function 2
- Reduces sympathetic nerve impulses from the vasomotor center to the heart and blood vessels, which explains its cardiovascular effects 1
Clinical Effects:
- Onset of action is delayed: expect 2-4 weeks before observing treatment effects, unlike stimulants which work immediately 3
- Provides "around-the-clock" coverage as a once-daily extended-release formulation 3
- Effect size is medium range and smaller than stimulants, making it generally a second-line treatment 3
Side Effects
Most Common Side Effects (from FDA label and clinical trials):
Very Common (>10% of patients):
- Somnolence/sleepiness (38.6% in clinical trials) - most frequently cited reason for discontinuation 1, 4
- Fatigue/tiredness 3, 1
- Headache (20.5%) 4
Common (5-10%):
- Low blood pressure (hypotension) 3, 1
- Low heart rate (bradycardia) - mean decrease of 13 bpm at 4mg dose 1
- Fatigue (15.2%) 4
- Nausea 1
- Stomach pain 1
- Dizziness 1
- Trouble sleeping/insomnia 3, 1
- Irritability 3
Serious Warnings (from FDA label):
- Hypotension and bradycardia - requires blood pressure and heart rate monitoring 1
- Fainting (syncope) 3
- Sedation - avoid driving or operating machinery until you know how it affects you 1
- Cardiac conduction abnormalities 3
- Rebound hypertension with abrupt discontinuation - must taper gradually 1
Important Safety Considerations:
Approximately 80% of patients experience at least one treatment-emergent adverse event (compared to 66.5% with placebo), though most are mild to moderate in severity 4, 5.
Discontinuation rates due to side effects: 19.8% in adults 5, with somnolence being the primary reason 6.
Clinical Pearls:
- Evening dosing is generally preferable due to frequent somnolence/fatigue, though morning dosing is also acceptable 3
- Avoid high-fat meals - increases drug exposure by ~75% for peak concentration and ~40% for total exposure 1
- Must swallow tablets whole - do not crush, chew, or break 1
- Children (ages 6-12) have higher drug exposure than adolescents and adults due to lower body weight, requiring careful dose titration 1
- Not interchangeable with immediate-release guanfacine on a mg-for-mg basis - extended-release has 58% relative bioavailability compared to immediate-release 1